Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
Rami Elghandour, the President, CEO, and Chairman of the Board of Arcellx , Inc. (NASDAQ:ACLX), a biotechnology company with a market capitalization of $3.4 billion, recently executed a series of stock transactions, according to a recent SEC filing. According to InvestingPro data, the company maintains strong financial health with a "GOOD" overall rating. On February 26, 2025, Elghandour sold a total of 38,300 shares of Arcellx common stock, generating proceeds of approximately $2.38 million. The sales were conducted at prices ranging from $61.138 to $62.6894 per share. The stock has experienced an 8% decline over the past week, with investors anticipating the company’s next earnings report on March 20, 2025.
These transactions were broker-assisted sales to cover tax withholding obligations related to the vesting of restricted stock units. Following these sales, Elghandour holds 149,186 shares of Arcellx in direct ownership. For comprehensive insider trading analysis and additional insights, including 8 more exclusive ProTips, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Arcellx Inc. has been the subject of attention following the release of new data on its developmental therapy, anito-cel, aimed at treating relapsed/refractory multiple myeloma. Analysts from Stifel have reiterated their Buy rating with a price target of $122, noting the potential market adoption of anito-cel due to its favorable safety profile compared to cilta-cel. The data presented at the American Society of Hematology 2024 meeting highlighted the absence of Parkinsonism in over 150 patients, which was seen as a positive indicator for the therapy’s safety. Similarly, TD Cowen maintained its Buy rating, emphasizing anito-cel’s comparable efficacy to Carvykti and its superior safety profile, including lower cytokine release syndrome rates.
BofA Securities also adjusted its outlook on Arcellx, raising the price target to $112 from $100, citing the interim pivotal iMMagine-1 data that supports anito-cel’s competitive profile. The firm expects Arcellx to capture a larger market share, projecting an increase from 45% to 50%. Analysts have praised Arcellx’s manufacturing capabilities, which are seen as advantageous in the competitive cancer treatment market. These developments have led to continued positive assessments and optimism about Arcellx’s potential in the industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.